Monday, October 26, 2026

Gold Posts Worst Monthly Drop in Decade as Central Bank Buying Streak Halts

Gold prices suffered their steepest monthly decline in over a decade in March 2026, reversing a rally driven by 15 consecutive months of central bank purchases. China and other emerging market central banks had pushed gold to record highs through early 2026 by diversifying reserves away from the U.S. dollar. The abrupt reversal signals a potential shift in reserve management strategies despite Goldman Sachs maintaining elevated price forecasts.

LM Salvado
LM Salvado

April 9, 2026

Gold Posts Worst Monthly Drop in Decade as Central Bank Buying Streak Halts
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Gold experienced its worst monthly decline in more than a decade in March 2026, ending a sustained rally fueled by emerging market central bank demand.1

China's central bank had extended gold purchases for 15 consecutive months through January 2026, part of a broader diversification strategy away from U.S. dollar reserves.1 This buying campaign, joined by other emerging market monetary authorities, drove gold to all-time highs in early 2026.

The March reversal marks a sharp break from this pattern. Central banks had been the primary driver of gold's bullish cycle, with their reserve management decisions carrying more weight than traditional investment flows. The sudden halt in this accumulation trend suggests either a strategic pause or a fundamental reassessment of portfolio allocation.

Goldman Sachs maintained elevated price targets for gold even as the March selloff unfolded, creating a disconnect between Wall Street forecasts and central bank behavior.1 This divergence raises questions about whether analysts have fully incorporated the changing dynamics of official sector demand.

For traders, the reversal presents a crucial test of gold's support levels. The metal had traded largely on central bank narratives rather than traditional inflation hedging or dollar weakness themes. Without sustained official sector buying, gold must find new demand drivers to stabilize.

The timing of the reversal also warrants attention. March 2026 coincides with shifting monetary policy expectations across major economies. If emerging market central banks are responding to changing interest rate differentials or currency pressures, their pause in gold accumulation could extend beyond a single month.

Market participants now face a critical question: whether March represented a temporary cooling or the end of the multi-year central bank buying cycle. The answer will likely determine gold's trajectory through the remainder of 2026.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· April 4, 2026
    Goldman Sachs has blunt message on gold price for rest of 2026

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com